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There is considerable concern within the
scientific community and media that the
increasing occurrence of endocrine-related
abnormalities in humans and wildlife may
be associated with exposure to environmen-
tal pollutants capable of mimicking or
modulating the action ofnatural hormones.
Appreciation that many ubiquitous com-
pounds of natural and anthropogenic ori-
gins are estrogenic has led to the hypothesis
that exposure to such compounds in utero
may be involved in falling sperm counts
and disorders ofthe male reproductive tract
(1). Although such estrogenic compounds
are structurally heterogeneous (2), there are
similarities including lipophilicity that facil-
itate accumulation in food-producing ani-
mals and potentiate risks associated with
entry into the human food chain (3). In the
United Kingdom these concerns have been
given added impetus following a report by
the Institute for Environment and Health
(4), which made several recommendations
aimed at investigating the risks.ofhormonal
mimics; these included the need to develop
robust and reliable assays capable ofscreen-
ing chemicals for estrogenic activity. Given
that prediction of estrogenic potency
through structural information alone is not
yet possible, development of such generic
assays is necessary because many existing
assay systems are not sufficiently robust for
nonexpert operation or may not accurately
reflect human potency.
Methods of detecting and assessing
estrogenic compounds have been previous-
ly described (5) and critically evaluated (6).
Biotransformation and consequent alter-
ation of hormonal activity by test systems
is an important consideration because phe-
nolic metabolites produced by the action
ofcytochrome P450 enzymes can be more
potent than the parent compounds (7,8).
Clearly, although such metabolic effects
are intrinsic to in vivo models, they may
not be so readily reflected by in vitro test
systems. Estrogen-sensitive human breast
cancer cells, such as MCF-7 cells, express
the human estrogen receptor and have
been used to develop E-screen tests for
chemicals (9) and contaminants in animal
feeds (10). Uterotrophic assays such as the
classical mouse uterine weight bioassay
(11) have limitations (6), but are still pre-
ferred methods for many investigators
(12). Uterotrophic assays also offer the
potential to combine biochemical and his-
tological analysis of estrogen-mediated
events and further adaptation to measure
antiuterotrophic activity (13).
The use ofreceptors linked to reporter
genes in transformed cellular systems to
detect biologically active xenobiotics has
been proposed as a strategy to define
chemicals by their functional properties (2).
This approach facilitates detection of not
only receptor ligand binding but also
response element occupancy and gene activa-
tion. The recombinant yeast cells used in the
present report have recently been used in an
ultrasensitive RCBAfor the determination of
prepubertal plasma estrogens (14). These
cells contain an expression plasmid that
indudes the CUPI metallothionein promot-
er fused to the human estrogen receptor
cDNA and a reporter plasmid which con-
tains two copies of the frog vitellogenin
estrogen response element upstream of the
yeast iso-i-cytochrome c promoter fused to
the structural gene for P-galactosidase.
Similar recombinant yeast cell systems have
been used for the detection ofxenoestrogens
(15,16) and various estrogen receptor studies
(17-19). The particular advantage of the
transformed yeast cell line approach is that
the cells are robust and substrate auxotrophy
may be used to continuously select for estro-
gen sensitivity. Moreover, expression of
human estrogen receptor and ability to auto-
mate suggest that these yeast cells have much
to offer the analyst requiring an in vitro
screening assay that affords some reflection
ofpotential estrogenic activityinhumans.
In the present study, bioassays were
evaluated by comparison of the potency of
test compounds relative to 17p-estradiol
(E2) since this natural estrogen is the most
commonly accepted positive control used in
such in vivo and in vitro assays (20,21).
Validation of the recombinant yeast cell
bioassay (RCBA) is addressed through com-
parison of potency values with an alterna-
tive established in vivo bioassay and with
potency values produced using similar in
vitro assays described in the literature.
Similar approaches to validation have been
commonly used (6,20) and serve to identify
some of the merits and limitations of an
assay relative to other in vitro and in vivo
methods. The metabolic fate of test com-
pounds in the selected bioassay is another
Address correspondence to M.J. Sauer, BPP
(Biochemistry Department), Veterinary
Laboratories Agency, New Haw, Addllestone, Surrey
KT15 3NB United Kingdom.
Work at the Veterinary Laboratories Agency was
supported by the Ministry ofAgriculture, Fisheries
and Food, U.K and at Duke University Medical
Center by NIH grant DK48807.
Received 3 March 1997; accepted 6 March 1997.
Volume 105, Number 7, July 1997 * EnvironmentalHealth Perspectives 734Articles * Recombinant yeast cell estrogen screening bioassay
Table 1. Comparison of RCBA results and estrogenic potencies described in the literature
Sourcea Compound tested RP RIE RPL
1 Steroidal estrogens
1 17P-Estradiol
1 17)3-Estradiol-3(f-D-glucuronide)
1 17P-Estradiol-3-sulfate
1 17P-Estradiol-3-glucuronide-
1 17-sulfate
1 17a-Estradiol
1 Estrone
1 Estriol
Steroids
1 Cholesterol
1 Androstenedione
1 Testosterone
1 Androstenediol
1 Dehydroepiandrosterone
1 Cortisol
1 Progesterone
1 D-Norgestrel
Synthetic estrogens
1 17a-Ethynylestradiol
1 Mestranol
1 Diethylstilbestrol
1 Hexestrol
1 Dienestrol
Triphenylethylene antiestrogens
1 Tamoxifen
1 4-Hydroxytamoxifen
1 Nafoxidine
Fungal resorcyclic acid lactones
1 Zearalenone
1 a-Zearalenol
1 3-Zearalenol
1 a-Zearalanol (zearanol)
1 ,B-Zearalanol
2 Phytoestrogens
2 Coumestrol
2 Equol
2 Daidzein
2 Formononetin
2 Bochanin A
2 Genistein
4-Alkylphenols
3 4-Nonylphenol (technical grade)
4 4-Nonylphenol (straight chain)
3 4-Octylphenol
3 4-tert-Octylphenol
Organochlorines
1 DDT
6 o',p'-DDT
6 o',p'-DDE
5 2,3,7,8-Tetrachlorodibenzo-p-dioxin
3 Methoxychlor
6 4'-Chloro-4-biphenylol
6 2'-Chloro-4-biphenylol
6 2',5'-dichloro-4-biphenylol
6 2',4',6'-Trichloro-4-biphenylol
6 2',3',4',5'-Tetrachloro-4-biphenylol
6 3,3',5,5'-Tetrachloro-4-4'-biphenyidiol
Other contaminants
1 Bisphenol A
1 Di-n-butylphthalate
6 Butylbenzylphthalate
1 Bis(2-ethylhexyl)phthalate
1 Butylhydroxytoluene
100
0.32
0.01
0
100
89.6
20.4
0
5.25 100
9.6 100
0.63 88
0
0
0.001
0.023
0.0018
0
0
0.0004
0
0
0.8
31
1.2
0
0
3.1
49b, 8c
5d66b 8C
16b,14c
0.01c
0.01C
0.01C
88.8 100 191b, 95c
7.3 80 8b
74.3 100 246k, 73c,73e
30.6 89 74b 55C,31ge, 5f
25.4 84 26c, 102e
0.0047
0.0073
0
0.26
8.7
0.066
1.3
0.46
0.67
0.085
0.0013
0.0056
0.0091
0.049
0.005
0.0022
0.003
0.00036
0.00003
0.00011
0.00004
0.26
0.0033
0.06
0.0037
0.62
1.0
0.82
0.016
0.005
0
0.0004
0
0
46
56
0
91 1.4c, 0.85e,0.5f
67 27c
58 0.43C, 0.043e, 0.07f
84 17c, 47e
3.4C
75
50
5.4
23
61
61
0.11w
0.2c
0.000728, 0.01 f
0.0004e
0.0048e, 0.0005f
0.08e, 0.011f
57 0.0039
38.3 -
22.3 0.039
43 -
0.8 -
2.4 -
1.0 -
5.5 --
55 -
73.3 0.0251
32 -
65 0.198h
67.6 2.38h
77 1.W
83.5 0.074
51 0.003, 0.05-0.02i
0 -
5.3 0.00039
0 -
0 -
important element of assay validation that
is addressed because this helps to provide a
better understanding of the significance of
experimental observations.
Materials and Methods
Source ofchemicals. [3H]Coumestrol (518
GBq/mmol; custom synthesis), di-n-butyl
[carboxyl-14C]phthalate (962 MBq/mmol),
[monoethyl-3H]diethylstilbestrol (3.4
TBq/mmol), 4-n-nonyl[ring 2,6(n)-3H]phe-
nol (1.96 TBq/mmol; custom synthesis),
[6,7-3H]17,-estradiol (1.89 TBq/mmol),
[3H]testosterone (3.88 TBq mmol), and a-
[3H]zeranol (1.92 TBq/mmol; custom syn-
thesis) were obtained from Amersham
International (Little Chalfont, U.K.).
Radiochemical purity was checked by radio-
HPLC usingthe conditions described below
and found to be greater than 96% in all
cases. Sources of chemicals tested for estro-
genicpotencyareprovided inTable 1.
Transformedyeast cells. Recombinant
estrogen sensitive yeast cells (14) were stored
in 30% glycerol at -80°C and grown as
required at 30°C on selective media agar
plates containing 0.17% yeast nitrogen base
(without amino acids and ammonium sul-
fate), 0.5% (NH4)2SO4, 2% dextrose, L-
leucine (60 pg/ml), L-histidine (20 pg/ml)
and 2% Bacto agar (Difco, East Molsey,
U.K.).
RCBA ofestrogens. Procedures that were
followed were similar to those described
previously (14). Briefly, a small colony of
(Table 1 continued) 3-glactosidase activity
achieved wth the test compound and that of E2 x
100; RPL, relative potencyvalues compared to 1713-
estradiol derived using molar mass units sourced
from the literature as indicated by the superscript.
Where necessary, data were normalized relative to
E2 (100). Maximum concentration of 2,3,7,8-tetra-
chlorodibenzodioxin tested was 100 nM.
aSources of chemicals: 1, Sigma Chemical
Company, Poole, Dorset, U.K.; 2, Apin Chemicals
Ltd., Abingdon, Oxon, U.K.; 3, Lancaster Synthesis
Ltd., Morecambe, Lancashire, U.K.; 4, Aldrich
Chemical Company, Gillingham, Dorset, U.K.; 5,
Promochem Ltd.,Welwyn Garden City, Herts, U.K.;
6, Mallinckrodt Baker, Milton Keynes, Bucks, U.K.
bCompetitive binding radioreceptor assay; data
from Korenman (21).
cCompetitive binding radioreceptor assay; data
from Arts and Van Den Berg (22).
dE2 receptor processing; data from Gyling and
Leclercq (23).
9MCF-7 cell proliferation assay; data from
Welshons et al. (10).
fHeLa cell cotransfection assay; data from
Miksicek(20).
gRelative proliferative potency in E-screen assay;
data from Sonnenschien, etal. (24).
hCompetitive binding radio-receptor assay; data
from Korach et al. (8).
'Competitive binding radioreceptor assay-proges-
terone receptor induction; data from Krishnan et
al. (25).
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yeast cells was sampled from an agar plate
and incubated for 18 hr at 30°C by continu-
ous shaking in 2 ml selective media broth.
The yeast cells were collected by centrifliga-
tion and diluted in 1 M mannose to an opti-
cal density of 0.1 (A630). Yeast cell suspen-
sion was dispensed (20 pl) into wells of96-
well plates (Nunc; LifeTechnologies, Paisley,
U.K) containing 75 1Ai of50 pM copper sul-
fate in selective media and incubated with 25
pl calibration standard. Calibration standards
were prepared in ethanol at a concentration
of10 mM andseriallydiluted (x 10) in selec-
tive media broth. After an 18-hr incubation
at 30°C, theyeast cell densityin thewellswas
estimated from the optical density at 630 nm
using a Dynatech microtiter plate reader
(Dynatech Labs, Billingshurst, U.K.).
Induction of J-galactosidase activity was
measured by addition of 100 1il Z buffer (60
mM Na2HPO4, 40 mM NaH2PO4, 10 mM
KCl, 50 mM mercaptoethanol, 1 mM
MgSO4) containing 2 mg/mIl o-nitrophenyl-
P-D-galactopyranoside (ONPG), 0.1% sodi-
umdodecyl sulfate, and 250 units/mllyticase
(Sigma Chemical Co., Poole, Dorset, U.K.)
to each well, and quantified by determina-
tion ofo-nitrophenol production expressed as
(OD410nm/ OD630nm) x 1000/min. Wells
were read at 6 min and at 4 hr according to
thelevel ofinduced I-galactosidase activity.
RCBA ofantiestrogens. ,B-Galactosidase
activity induced by E2 (100 fM-100 nM)
in the presence of the potent antiestrogen
4-hydroxytamoxifen (1 nM-10 pM) was
investigated with recombinant yeast cells as
described above.
Estrogenic potency oftest compounds in
RCBA. A range ofchemicals was tested for
estrogenic activity in at least two separate
experiments using the RCBA. Calibration
curves of E2 and test compounds were pro-
duced by analysis ofstandards (100 fM-10
nM for E2 and potent estrogens and 10
pM-10 pM for weak estrogens) in selective
media for estrogenic activity. Each calibra-
tion standard of a test compound was ana-
lyzed in 8 wells (1 column) and assay blanks
(vehide only) in 16 wells (2 columns) of a
96-well microtitre plate. Each testcompound
was assayed in a separate 96-well microtitre
plateand thewellsweresealedwith filmplate
sealers. P-Galactosidase activity in blankwells
(typicallyOD410,I 0.080 ± 0.012 and 0.109
± 0.009 at 6 min and 4 hr, respectively) was
subtracted from wells containing standard
concentrations oftest chemicals. The relative
potency of test compounds was determined
from the concentration ofE2 and test com-
pound that provided 50% induction of0-
galactosidase activity (EC50) and calculated
by dividing the E2 EC50 by the test com-
poundEC50 x 100. The relative potency of
weak estrogens that failed to induce [-galac-
tosidase to 50% of the total E2 activity was
determined from theconcentration ofE2 and
test compound that provided the same
induction of[-galactosidase activity and cal-
culated similarly. The relative inductive effi-
ciency (RIE) was determined as the ratio of
maximal 0-glactosidase activity induction
with testcompoundto E2 x 100.
Uterotrophic assay. Prepubertal 18-day-
old CFLP female mice (Harlan U.K. Ltd.,
Huntingdon, U.K.) were injected subcuta-
neously with 0.1 ml test compound dis-
solved in corn oil at the doses shown in
Table 2, on three consecutive days, essential-
ly as described by Rubin et al. (11). In each
assay, five concentrations of E2 (calibrant)
and three concentrations oftest compound
were injected using seven animals per dose.
Mice were sacrificed on the fourth day and
theweights ofthe animal and uteri recorded;
a sample ofvagina was fixed in phosphate
buffered saline containing 1% formaldehyde
and processed for routine histological evalua-
tion. Results are expressed as the mean ratio
ofuterine weight to body weight. The rela-
tive potency of test compounds was deter-
mined by interpolation from calibration
curves ofthe molar dose ofE2 and test com-
pounds that provided similar increases in
ratios of uterine wt/body wt x 100. Care
and treatment ofthe micewas in accordance
with theAnimals (Scientific Procedures) Act
1986 of the United Kingdom and super-
vised byaveterinary surgeon.
Human breast cancer cellproliferation
assay. MCF-7 human breast cancer cells
were maintained in Eagles minimal essential
medium (EMEM) supplemented with 5%
Table2. Effect oftestcompounds on prepubertal mouse uterine weight and comparison with the RCBA
Relative Relative
Uterine wt/body uterotrophic potency
Compound Dose wtratio (mean ± SD) potency (molar) (RCBA)
Control 0 0.097 ± 0.030 - -
17P-Estradiol 5 ng 0.172± 0.028** 100 100
10 ng 0.247 ±0.030 -
25ng 0.405±0.114# -
50 ng 0.420 ±0.121' -
100ng 0.554±0.126# -
Diethylstilbestrol 0.5 ng 0.076 ± 0.029 234 74.3
5 ng 0.137 ± 0.034** -
50 ng 0.715± 0.260** -
4-Nonylphenol (technical 0.5 mg 0.086 ± 0.030 0.00036 0.005
grade, Sigma) 1 mg 0.094 ± 0.021 -
5 mg 0.351 ± 0.192*
20mga - -
4-Octylphenol 0.5 mg 0.074 ± 0.034 0 0.003
1 mg 0.097 ± 0.034 -
5 mg 0.085 ± 0.036 -
Coumestrol 1 pg 0.104 ± 0.026 0.024 0.67
10pg 0.132 ±0.009 - -
100 pg 0.436 ±0.182# - -
Benzylbutylphthalate 0.05 mg 0.086 ± 0.024 0 0.0004
0.5 mg 0.093 ± 0.031 -
5 mg 0.108± 0.027 -
Dibutylphthalate 0.05 mg 0.119 ± 0.036 0 0
0.5 mg 0.101 ± 0.028 -
5mg 0.091 ± 0.014 -
a-Zearalanol 1 pg 0.139 ± 0.029** 0.026 1.3
10pg 0.190±0.035# - -
100 pg 0.411 ± 0.27* - -
Bisphenol A 0.05 mg 0.098 ± 0.014 0 0.005
0.5 mg 0.092 ± 0.021 -
5mg" _ _
Abbreviations: RCBA, recombinant yeast cell bioassay; SD, standard deviation. Potency values deter-
mined with the murine uterotrophic assay are presented with the RCBAfor comparison. Statistical signifi-
cance is relative to untreated controls.
aAnimalsfrom this treatment group were withdrawn from the study due totoxic effects ofthe dose.
*p<0.05; **p<0.01;#p<0.001.
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(v/v) fetal calfserum (FCS), 20 mM HEPES,
2 mM glutamine nonessential amino acids,
0.075% sodium bicarbonate, and 600 ng/ml
insulin. The proliferative effect of E2 was
determined by seeding 5 x 104 cells into
replicate 25-cm2 flasks (four per E2 concen-
tration) in EMEM supplemented as above.
After 3 days incubation, the seeding medium
was removed and the monolayers were
washed with Earle's balanced salt solution
(phenol red-free) and replaced with medium
containing phenol red-free EMEM, dextran
charcoal stripped FCS, supplemented as
above with the exception of insulin. After a
further 3-day incubation period to enable the
MCF-7 cells to return to basal estrogen non-
stimulated status (10) the cultures were treat-
ed with medium containing E2 (1-10,000
pM dissolved in ethanolvehide) and incubat-
ed for 5 days. The cell number per flask was
determined by counting cell nuclei as
described previously (26).
Biotransformation ofsteroids and
xenoestrogens by yeast cells. Recombinant
yeast cells were suspended at an appropri-
ate dilution in minimal media so as to pro-
vide an optical density of 0.1 (A630 nm);
these and similar blank cultures (without
yeast cells) were incubated at 30°C with
100 nM 37 KBq/ml tritium labeled
coumestrol, E2, diethylstilbestrol, 4-
nonylphenol, testosterone, and a-zearanol
and 10 pM [14C]di-n-butylphthalate for
18 hr. The medium was sampled after
incubation periods of 1, 4, and 18 hr; it
was then centrifuged and stored at -20°C
prior to analysis by radio-HPLC.
Metaboliteanalysis. Samples ofmedium
were analyzed for the presence of metabo-
lites by reverse phase radio-HPLC using
either a Hypersil BDS C18 3 pm 100 x 4.6
mm (Life Sciences International, Runcorn,
U.K.) or aSpherisorb ODS 5 pm 250 x 4.6
mm (Jones Chromatography, Hengoed,
U.K.) column (for di-n-butylphthalate
only) and chromatographed at a flow rate of
1 mI/min. Conditions were selected to pro-
vide separation ofparent compounds from
metabolites using conditions similar to
those described previously (27). Di-n-
butylphthalate, testosterone, and E2 analysis
used an isocratic mobile phase consisting of
35% acetonitrile:65% water for 15 min and
a-zeralanol, coumestrol, and diethylstilbe-
strol analysis used a linear gradient mobile
phase system consisting of 50:50 water
methanol containing 0.1% acetic acid to
100% methanol, 0.1% acetic acid, over 25
min. 4-Nonylphenol analysis employed a
linear gradient from 20:80 methanol:water
to 100% methanol over 15 min, which was
maintained for an additional 5 minutes.
The above studies were all conducted at
the Central Veterinary Laboratory, United
20,000
1,000
r-
a
SL.
S
a
100
10-17 1o-1S 10-15 10"-4 10-13 10-12
E2dose (mol)
Figure 1. 173-Estradiol (E2) calibration curves derived from the recombinant yeast cell bioassay (RCBA; n
= 8), the MCF-7 human breast cancer cell proliferation assay (n = 4), and the prepubertal mouse
uterotrophic assay (n =7). Induction of galactosidase activity (RCBA), increase in cell number (MCF-7 cell
proliferation assay), and uterine weight (prepubertal mouse uterine weight assay) were normalized to
percentage response and are plotted against the total number of moles of E2 added to the test system.
Error bars represent ± 1 standard deviation.
*p<0.05; **p<0.01;#p<0.001 relative to values obtained inthe absence of E2.
10,000 -.
*E2 * Coumestrol
Equol
1,000 * BisphenolA
* 4-Nonylphenol
A Zearalenone l= lI1II1!i
A Diethylstilbestrol
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ioo -_i ** |1II I l
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Concentration (M)
Figure 2. Typical calibration curves for 1713-estradiol (E2), coumestrol, equol, bisphenol A, 4-nonylphenol,
zearalenone, diethylstilbestrol, and benzylbutylphthalate derived from the recombinant yeast cell bioas-
say. Error bars represent ± 1 standard deviation (n = 8).
Kingdom, betweenJuly 1995 and February
1997.
Results
Evaluation ofbioassay sensitivity toE. The
sensitivity of the RCBA, MCF-7 human
breast cancer cell, and uterotrophic bioassays
were compared byevaluation ofrespective E2
calibration curves. Direct comparison of the
two in vitro assays with the in vivo assay was
enabled by conversion of the concentration
units ofE2 used in the RCBA (100 fM-100
nM) and the MCF-7 proliferation (1-10,000
pM) bioassays to total moles added to the in
vitro system during the assay because this
could be equated with the quantity of
Environmental Health Perspectives * Volume 105, Number 7, July 1997
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administered dose (mole per mouse) used in
the in vivo mouse uterotrophic assay. The
endpoints recorded for each bioassay, namely
induction ofj-galactosidase activity (RCBA),
increase in cell number (MCF-7 cell prolifer-
ation assay), or uterine weight (prepubertal
mouse uterine weight assay), were normal-
ized to percentage response. E2 significantly
(Students t-test) increased RCBA (-galactosi-
dase activity (p<0.01), MCF-7 cell prolifera-
tion (p<0.05), and uterine weight (p<0.01) at
total doses of10-17, 5 x 10-15, and 1.83 x 10-
moles respectively, relative to controls.
E2 calibration curves generated with
these three bioassays are shown in Figure 1.
In terms of molar dose, the RCBA was
approximately two and five orders ofmagni-
tude more sensitive to E2 than the MCF-7
cells and uterotrophic bioassays, respectively.
The dynamic range of percentage response
to E2 [mean ± standard deviation (SD)] was
at least an order ofmagnitude greater for the
RCBA (17.37 ± 10.8-7754 ± 3370%) than
either the MCF-7 proliferation (30 ±
13-175 ± 25%) or uterotrophic (79 ±
28-472 ± 130%) bioassays. E2 calibration
curves for the recombinant yeast cell and
uterine weight bioassays without prior data
normalization are shown in Figure 2 and
Table 2, respectively. Potential interference
ofestrogenic residues leaching from theplas-
tic microwells in the RCBA was determined
by comparing E2 calibration curves prepared
in untreated and washed (5 times with 0.1
ml ethanol) 96-well plates. No significant
difference between either blankvalues (wells
without E2) or E2 calibration curves pre-
pared in the different plates was found.
Application ofthe RCBA to test com-
pounds. Treatment of recombinant yeast
cells with estrogens for 18 hr produced
dose dependent increases in 3-galactosidase
activity of approximately 2-3 orders in
magnitude. Typical dose-response curves
(not all from the same experiment) for E2,
coumestrol, equol, bisphenol A, 4-
nonylphenol, zearalenone, and butylben-
zylphthalate are shown in Figure 2.
Relative estrogenic potency and induc-
tive efficiency oftest compounds in the
RCBA. Dose-response curves for 53 chemi-
cals were produced using the RCBA; from
these, estrogenic potency and maximal ,-
galactosidase induction values relative to E2
were determined (Table 1). The synthetic
stilbenes diethylstilbestrol, hexestrol, and
dienestrol and the synthetic steroid 17a-
ethynylestradiol had the highest relative
potencies and were ofa similar order to E2.
Environmental pollutants such as the 4-
alkylphenols were among the weakest estro-
gens tested, with relative potencies 4-5
orders of magnitude less than E2. Steroids
including cholesterol, androstenedione,
progesterone, and cortisol had either very
weak or undetectable estrogenic activity.
The triarylethylene antiestrogens nafoxidine,
tamoxifen, and 4-hydroxytamoxifen [a
potent metabolite of tamoxifen (28)] also
had weak estrogenic activity. Many of the
test compounds produced relative inductive
efficiencies ofless than 100%; this was taken
to indicate that they are partial estrogen
receptor agonists. Potency values ofsome of
the compounds tested with the RCBA were
also taken from literature sources and are
listed forcomparative purposes in Table 1.
Effect ofE2 + 4-hydroxytamoxifen in
RCBA. The effect of 4-hydroxytamoxifen
(10-9-10-5 M) and E2 (10-13-10-7 M), both
singly and in combination, onP-glactosidase
activity induction is shown in Figure 3. p-
Galactosidase activity was significantly stim-
ulated (p<0.05) by E2 (10-13_10-7 M) and by
4-hydroxytamoxifen (10-8_10-5 M) com-
pared with blank wells. The potential antag-
onist activity of 4-hydroxytamoxifen was
investigated by addition of4-hydroxytamox-
ifen (10-9-10-5 M) to E2 calibration curves
(10-13_-0-7 M). ,B-Galactosidase activity
stimulated by 1 nM E2 was significantly
reduced (p>0.05) by indusion of4-hydroxy-
tamoxifen (10-9-10-5 M) compared with 1
nM E2 alone, indicating antagonism of E2
binding; to darify this point, these data (box,
Fig. 3) are replotted as percentage inhibition
ofE2-stimulated P-galactosidase activity in
Figure 4. Similarly, ,B-galactosidase activity
stimulated by 10-8 and 0-7 M E2 was signif-
icantly reduced by combination with 10-6
and 10-5 M 4-hydroxytamoxifen compared
with E2 alone. 4-Hydroxytamoxifen dis-
played agonist activity when tested in isola-
tion; as a result, 3-galactosidase activity was
significantly (p>0.05) elevated by relatively
high doses of4-hydroxytamoxifen when test-
ed with a low dose ofE2 (e.g., 10-13 M E2 +
10-9_10-5 M 4-hydroxytamoxifen) when
comparedwith E2 alone (Fig. 3).
Determination ofrelative estrogenic
potency using the mouse uterine weight
assay. The uterotrophic effect and relative
estrogenic potencies of E2, diethylstibe-
strol, 4-nonylphenol, 4-octylphenol,
coumestrol, oa-zearalanol, bisphenol A,
dibutylphthalates, and benzylbutylphtha-
lates are shown in Table 2. 4-Nonylphenol,
coumestrol, at-zearalanol, and diethylstilbe-
strol significantly (p<0.05) increased uter-
ine weight at the doses shown. After the
first injection of the highest doses of 4-
nonylphenol and bisphenol A, symptoms
ofacute toxicity were evident and, as a con-
sequence, these mice were immediately
withdrawn from the study and euthanized.
Xenobiotic biotransformation. Analysis of
incubation medium revealed no evidence of
xenobiotic metabolism following incubation
ofyeast cells with E2, coumestrol, dibutylph-
thalate, diethylstilbestrol, testosterone, and 4-
nonylphenol. In the case of a-zearalanol, a
single metabolite (5% oftotal) was detected
in themedium after 18 hr (datanotshown).
Discussion
High sensitivity is an important requirement
for screening assays to enable detection of
compounds of low potency that may be of
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Figure 3. Calibration curves for 171-estradiol (E2) 100 fM-100 nM, 4-hydroxytamoxifen 10 pM-10 pM, and
E2 (100 fM-100 nM) in the presence of 0.001, 0.01, 0.1, 1, and 10 pM 4-hydroxytamoxifen with the RCBA.
Error bars represent 1 standard deviation (n = 8). Box indicates data also presented in Figure 4to illustrate
the inhibition of E2 (1 nM)-induced )-galactosidase activity by4-hydroxytamoxifen (1 nM-10 pM).
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biological significance through chronic
exposure and/or high abundance in the
environment. The effect of E2 on MCF-7
cell proliferation and uterotrophic activity
found in the present study was similar to
that observed in previous reports (10,11,29).
The recombinant yeast cells were designed
and engineered for exquisite sensitivity to
estrogens (17,30,31); overexpression of
human estrogen receptor, high amplitude
frogvitellogenin estrogen response elements,
and their tandem arrangement in the
reporter plasmid all serve to amplify[B-galac-
tosidase production and hence sensitivity to
E2 (14). However, evaluation ofthe relative
merits of these bioassays for estrogens can-
not be based on sensitivity criteria alone;
summary findings for the different assays
used in this report and a similar recombi-
nant yeast screen are presented for compari-
son in Table 3. Adaptation ofreporter gene
assays to the 96-well plate format enables
automation on standard laboratory instru-
mentation and a marked reduction in sam-
ple size. In contrast, the prepubertal mouse
uterotrophic assay requires a large mass of
sample, is relatively labor intensive, requires
the sacrifice of large numbers of animals,
and is sensitive to the potentially diverse
toxic effects oftest compounds.
Interaction ofactivated receptor-ligand
complex with human estrogen responsive
elements and the opportunity to measure
diverse estrogen-regulated gene products
such as the progesterone receptor is a rec-
ognized advantage of cancer cell-based
screens (24). Uterotrophic bioassays also
offer the simultaneous measurement of
other markers ofestrogen action including
vaginal and uterine cell proliferation, which
may be used to provide definitive confir-
mation of estrogenic activity (32). One
potential disadvantage of MCF-7 cells is
that under certain conditions they may also
express receptors for other classes of
steroids (33), and other hormones includ-
ing progestagens have been shown to
increase breast cancer cell proliferation
(34). Similarly, under certain circum-
stances uterotrophic assays are limited in
selectivity for estrogens by sensitivity to
androgens and progestagens (6). For these
reasons, expression ofsingle class ofsteroid
receptor, as in the RCBA system, is highly
desirable since this provides a system with
appropriate sensitivity and specificity to a
single class of hormone. Moreover, the
genetic simplicity of yeast cells separates
estrogen receptor signaling from the con-
founding affects of other signaling path-
ways in the cell.
Evaluation of the relative estrogenic
potency ofsteroids from different hormone
dasses is necessary to demonstrate and estab-
lish assay selectivity for estrogens. This
important element of assay validation also
provides a reference scale for estrogenic activ-
ity found with the RCBA relative to com-
pounds generally accepted to be either estro-
gens or without estrogenic activity. Many of
the compounds tested with the recombinant
yeast cell bioassay did not induce f3-galactosi-
dase activity to the same extent as E2. Similar
observations have been made with the E-
screen breast cancer cell proliferation assay
and were interpreted as indicating that the
xenobiotics tested were partial agonists (24).
Evaluation of estrogenic activity with the
RCBA in terms ofrelative potency alone can
be misleading because several androgens
(e.g., testosterone) have estrogenic potencies
of a similar order to those of, for instance,
the alkylphenols. Consideration must also be
given to the relative inductive efficiencyofP-
galactosidase activity by test compounds. In
this regard androgens were much weaker
estrogens than alkylphenols. Although
androgens have uterotrophic (6) and mito-
genic activity (35) at pharmacological doses
in vivo, they are unlikely to be ofphysiologi-
cal significance as estrogens because endoge-
nous concentrations are several orders of
magnitude less than used in such assays. A
slight response to testosterone has been
reported with a similar yeast screen for estro-
gens (15); indeed, the potency of testos-
terone foundwith the RCBAwas an order of
magnitude lower than that found with a
competitive binding radioreceptor assay (22).
Synthetic estrogens including 17a-
ethynylestradiol and the stilbenes were
among the most potent estrogens tested
comparable with E2. This contrasts with the
relative estrogenic potency of most of the
phytoestrogens and environmental pollu-
tants, which were several orders of magni-
tude less potent than E2. Phytoestrogens
have been ranked by potency in a HeLa cell
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Figure 4. Percentage inhibition of 173-estradiol (E2; 1nM) induced ,B-galactosidase activity in recombinant
yeast cells by 4-hydroxytamoxifen (1 nM-10 pM). Error bars represent 1 standard deviation (n = 8).
*p<0.05;#p<O.001.
Table 3. Comparison of assays used to determine estrogenic activity
Recombinant MCF-7 breast Mouse
Attribute RCBA yeastscreena cancercells uterotrophic assay
SensitivitytoE2 lOOfM 7.3pM (2 ng/1) 1 pM 18pmol
ER Human Human Human Mouse
Estrogen response elements Frog Notstated Human Mouse
Detection ofantiestrogenic activity Poor Nottested Good Good
Assayendpoints P-gal ,B-gal Cell proliferation, Uterineweight,
etc., e.g., PgR etc.(e.g., PgR)in
othertissues
(e.g.,vagina)
Steroid receptors expressed ER ER ER, PgR,AR, GR ER, PgR,AR, GR
Detection ofproestrogens No Notstated Limited ? Yes
Assayduration 18hr 3-4days 7days 4days
Automation in 96-well plateformat Yes Yes Yes No
Abbreviations: RCBA, recombinant yeast cell bioassay; )-gal,f-galactosidase assay; ER, estrogen recep-
tor; PgR, progesterone receptor; AR, androgen receptor; GR, glucocorticoid receptor.
aRecombinantyeast screen described by Routledge and Sumpter (15).
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cotransfection reporter gene assay (20) and
were found to operate as complete agonists
in this system. The phthalates and certain
organochlorines (DDT, o'p'-DDT, and
DDE) had little estrogenic activity in the
recombinant yeast cell bioassay in conflict
with other reports (9,36). Various factors
induding protein binding (16) and molecu-
lar permeation into the yeast cells (18),
which have not been considered in the pre-
sent study, cannot be excluded and maypro-
vide apartial explanation forthese discrepan-
cies. The transformed yeast cells used in the
RCBA are a stable cell line and, as such, are
robust and well suited for use by other labo-
ratories in further studies, which may reveal
the nature of these disparities and further
identify strengths and limitations of this
assay. Stimulation ofI-galactosidase activity
by 2,3,7,8-tetrachlorodibenzo-p-dioxin was
an unexpected but reproducible finding and
merits further investigation of the mecha-
nism. Competitive binding studies have
shown that 2,3,7,8-tetrachlorodibenzo-p-
dioxin does not bind to the estrogen recep-
tor, but dioxins can evoke estrogenic and
diverse potent antiestrogenic effects through
various cellular mechanisms (37,38).
Comparison of the relative estrogenic
potencyvalues derived from the RCBAwith
those using similar in vitro methods
described in the literature (Table 1) provides
a further basis for validation against current
methods. The RCBA produced relative
estrogenic potency values that were within
an order ofmagnitude ofthose described in
the literature with very few exceptions (e.g.,
daidzein). Indeed, variation ofthis order are
apparent between literature values (seeTable
1) both within and between laboratories
according to the particular assay used
(20,39). Both the RCBA and mouse
uterotrophic assay indicate that 4-nonylphe-
nol is a more potent estrogen than 4-
octylphenol, contrary to other reports
(24,40), although the potency of 4-
nonylphenol obtained with the RCBA was
very similar to the E-screen (24). Variation
in the estrogenic potency of some 4-tert-
nonylphenol preparations has been found
(15), raising the possibility that the purity of
chemicals may provide an explanation for
the disparity between assays; alternatively,
differences in biotransformation or those
inherent to the assay system are plausible
explanations. However, this comparative
study demonstrates that the RCBA provides
estimates ofrelative estrogenic potency that
are reproducible and broadly similar with
other in vitro methods. In addition to yeast
cells, reporter gene assays have also been
introduced into breast cancer cells and other
cell lines and produced comparable potency
values for alkylphenolic compounds (40).
Such reporter gene assays (19,20) and breast
cancer cell proliferation assays (10,24) are
typically sensitive to E2 at concentrations of
1 pM (Table 3).
4-Hydroxytamoxifen is a metabolite of
tamoxifen and a potent antiestrogen (28).
Although the RCBA demonstrates the abili-
ty of 4-hydroxytamoxifen to significantly
inhibit E2-induced P-galactosidase activity,
the response was onlyweak. The incomplete
suppression of E2-induced ,-galactosidase
activity observed may be due to the intrinsic
estrogenicity ofcertain triarylethlyene antie-
strogens like tamoxifen (41). Given the rela-
tively poor response to the potent antiestro-
gen 4-hydroxytamoxifen, it is anticipated
that this system would not have sufficient
sensitivity to detect weaker antiestrogens.
More significant inhibition of E2-induced
activity by triarylethylene antiestrogens has
been demonstrated in reportergene assays in
mammalian cells (19,20,40) and breast can-
cer cell proliferation assays (42). A yeast cell
system similar to the RCBA (18) was sensi-
tive to the estrogenic but not antiestrogenic
activity oftamoxifen. Thus, these data indi-
cate the need for further adjustment of
either the RCBA assay conditions or to the
plasmids that confer such extreme sensitivity
to estrogens to provide more sensitive detec-
tion of antiestrogenic activity. Various co-
activators and transactivating sequences have
been identified that may be required for
steroid receptor transcriptional activity and
discrimination between agonist- and antago-
nist-activated receptors in specific cell types
(43). Antiestrogens may also operate by
other cellular mechanisms induding antago-
nism ofcalmodulin-regulated processes (42)
to which steroid receptor reporter gene sys-
tems are likely to be insensitive. Assays with
the potential to detect antiestrogens are of
particular value because they may be impor-
tant in evaluating certain classes of com-
pounds such as the phytoestrogens and
dioxins, which may have antiestrogenic
activity and provide chemoprevention of
certain cancers (38,44).
In vivo bioassays for estrogenic activity
are ofparticular value because theyprovide a
means ofconfirming the potential biological
significance of in vitro findings (36). The
uterotrophic assay used in the present study
produced estrogenic potencies that were rela-
tively imprecise because only three doses of
test compound were assayed. Nonetheless,
with the exception ofdiethystilbestrol, lower
potency values were derived using the
uterotrophic assay compared with the
recombinant yeast cell assay. Moreover, sev-
eral compounds that have estrogenic activity
in vitro, induding thephthalates, 4-octylphe-
nol, and bisphenol A, had no detectable
uterotrophic activity. Histological evaluation
ofvagina sections enabled further confirma-
tion of estrogenic activity, as in all cases,
uterotrophic activity was associated with
cornification and thickening ofthe stratified
squamous epithelium. Clearly, the biological
significance ofvery weak estrogens detected
with highly sensitive in vitro bioassays
requires careful evaluation if activity in vivo
is absent or found only at very high doses,
which may exceed those giving rise to acute
in vivo toxicity. Pharmacokinetic parameters
(adsorption, metabolism, tissue distribution,
and excretion) may have a significant influ-
ence on estrogenic activity in vivo, which
cannot be readily accounted for in in vitro
assays. These and other inherent differences
between the RCBA and the murine
uterotrophic assay will produce different
potency values as found for diethylstilbestrol
and other chemicals shown in Table 2.
Chronic exposure in vivo may facilitate the
bioaccumulation of pollutants and their
metabolites and thereby give rise to estro-
genic activity not evident in acute (3 day)
uterotrophic studies. The current situation is
further complicated by recent conflicting
reports (45,46) relating to the potential for
substantial synergistic interactions between
xenoestrogens.
Biotransformation ofxenobiotics in vivo
is usually part of a process of deactivation
and elimination, but proestrogens (e.g., cer-
tain phytoestrogens and organochlorines)
may undergo metabolic activation to potent
estrogens in various body compartments.
Although the range ofcompounds tested for
biotransformation in the RCBAwas limited,
these studies provide valuable information
on the fate oftest compounds in this type of
system. The corollary to the absence ofsig-
nificant steroid and xenobiotic biotransfor-
mation by the recombinant yeast cells is
that, in their present form, they could not
be utilized for the detection ofproestrogens.
Proestrogen detection in vitro has been
accomplished by co-incubation of metabo-
lizing and estrogen detecting systems
(28,42). In this regard, transformed yeast
cellswould be suitable for combination with
an appropriate metabolizing system for the
detection of species-specific proestrogens
since there would be little interference from
yeast cell xenobiotic metabolism. By con-
trast, other mammalian cell assay systems
such as MCF-7 breast cancer cells will also
have the potential for significant steroid and
xenobiotic biotransformation; in isolation,
such intrinsic metabolism may confound
interpretation ofresults from a simple screen
for estrogenic activity. Although cytochrome
P450 activities are poorly maintained in
vitro by isolated cells, steroid metabolizing
enzymes, including aromatase, hydroxys-
teroid oxidoreductases, and estrogen sulfa-
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tase, have been described in human breast
cancer cells. Thus, a comprehensive knowl-
edge of intrinsic metabolic activity is
required before a test system can be fully
validated and acceptable as a gold standard
method.
Conclusion
The RCBA is a highly sensitive human
estrogen receptor-based screening assay for
the rapid detection ofestrogens. The estro-
genic potency and relative inductive effi-
ciency of 53 chemicals has been evaluated
with this system. Potency values produced
with the RCBA were similar to literature
values, but were generally higher than those
produced with a murine uterotrophic assay.
The mechanism through which TCDD
stimulates 0-galactosidase activity in the
RCBA warrants further investigation.
Because the RCBA cannot detect proestro-
gens and has limited sensitivity to antie-
strogens, further development is required
to broaden the application to the detection
of such compounds. The RCBA may be
suitable for use by regulatory bodies, such
as the FDA in the United States and the
Environment Agency in the United
Kingdom, as a simple, rapid, and inexpen-
sive method of evaluating intrinsic estro-
genic activity of wide-ranging chemical
classes and may provide a preliminary
means of evaluating the risk presented by
such chemicals to the public, wildlife, and
the environment.
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